Company intelligence / Profile preview

RinuaGene Biotechnology

Suzhou/Suzhou Industrial Park, Jiangsu Sheng/Jiangsu Province, Chinarinuagene.com ↗

Ownership: Private
Development stage: Phase 1

Overview

RinuaGene’s lead candidate RG002—an mRNA-LNP therapeutic vaccine targeting high-risk HPV—received FDA IND approval in October 2023 for CIN II/III. It represents the world’s first approved mRNA-LNP therapeutic vaccine IND for this indication. Preclinical data show strong immunogenicity and tumor regression in animal models. Clinical trials are ongoing; no published human efficacy results yet

Therapeutic areas: OncologyInfectious DiseasesWomen's Health
Modalities: mRNA therapeuticsmRNA vaccinesLipid nanoparticle (LNP) delivery
Industry: Biotech

Drug pipeline

5 assets

RG002

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on RinuaGene Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RinuaGene Biotechnology.

Explore the full profile